Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Barinthus Biotherapeutics (BRNS) Consolidated Net Income (2020 - 2026)

Barinthus Biotherapeutics (BRNS) has disclosed Consolidated Net Income for 7 consecutive years, with -$5.5 million as the latest value for Q1 2026.

  • For Q1 2026, Consolidated Net Income rose 71.85% year-over-year to -$5.5 million; the TTM value through Mar 2026 reached -$52.3 million, up 19.88%, while the annual FY2025 figure was -$66.5 million, 8.62% down from the prior year.
  • Consolidated Net Income hit -$5.5 million in Q1 2026 for Barinthus Biotherapeutics, up from -$11.1 million in the prior quarter.
  • Across five years, Consolidated Net Income topped out at $15.7 million in Q2 2022 and bottomed at -$23.8 million in Q2 2023.
  • Average Consolidated Net Income over 5 years is -$11.8 million, with a median of -$15.5 million recorded in 2024.
  • Year-over-year, Consolidated Net Income skyrocketed 248.69% in 2022 and then tumbled 807.96% in 2023.
  • Barinthus Biotherapeutics' Consolidated Net Income stood at -$21.2 million in 2022, then rose by 18.3% to -$17.3 million in 2023, then dropped by 19.09% to -$20.6 million in 2024, then soared by 46.08% to -$11.1 million in 2025, then skyrocketed by 50.16% to -$5.5 million in 2026.
  • According to Business Quant data, Consolidated Net Income over the past three periods came in at -$5.5 million, -$11.1 million, and -$14.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.